- TRADE NAME: Pifeltro (Merck Sharpe & Dohme)
- INDICATIONS: indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history.
- CLASS: Non-nucleoside reverse transcriptase inhibitor
- HALF-LIFE: 15 hours
- FDA APPROVAL DATE: 08/30/2018
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Efavirenz, Enzalutamide, Etravirine, Mitotane, Nevirapine, Oxcarbazepine, Phenobarbital, Phenytoin, Rifabutin, Rifampin, Rifapentine, St John's Wort - PREGNANCY: No adequate data to establish risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
